Crosstalk with insulin and dependence on PI3K/Akt/mTOR rather than MAPK pathways in upregulation of basal growth following long-term oestrogen deprivation in three human breast cancer cell lines

Hormone Molecular Biology and Clinical Investigation

Volumn 5, Issue 2, 2011, Pages 53-65

  Ray, Swagat ^a   Darbre, Philippa D ^a  

^a UNIVERSITY OF READING   (United Kingdom)

Author keywords

Akt; breast cancer cells; endocrine resistance; insulin; MAPK; MCF 7 cells; mTOR; oestrogen; oestrogen deprived; PI3K; picropodophyllin; rapamycin; T 47 D cells; ZR 75 1 cells

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; ESTRADIOL; INSULIN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHENOLSULFONPHTHALEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAF PROTEIN; RAPAMYCIN;

ARTICLE; BREAST CANCER CELL LINE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL LYSATE; CELL PROLIFERATION; CONTROLLED STUDY; CULTURE MEDIUM; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

EID: 84916624320     PISSN: 18681883     EISSN: 18681891     Source Type: Journal    
DOI: 10.1515/HMBCI.2010.072     Document Type: Article

References (58)

1. Miller WR. Estrogen and breast cancer. London: Chapman and Hall., 1996.
2. Lonning PE. Endocrinology and treatment of breast cancer. Clin Endocrinol Metab 2004;18:1-130.
3. Katzenellenbogen BS., Kendra KL., Norman MJ., Berthois Y. Proliferation., hormonal responsiveness., and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens. Cancer Res 1987; 47:4355-60.
4. Welshons WV., Jordan VC. Adaptation of estrogen-dependent MCF-7 cells to low estrogen (phenol red-free) culture. Eur J Cancer Clin Oncol 1987;23:1935-9.
5. Murphy CS., Meisner LF., Wu SQ., Jordan VC. Short- and long-term estrogen deprivation of T47D human breast cancer cells in culture. Eur J Cancer Clin Oncol 1989;25:1777-88.
6. Daly RJ., Darbre PD. Cellular and molecular events in loss of estrogen sensitivity in ZR-75-1 and T-47-D human breast cancer cells. Cancer Res 1990;50:5868-75.
7. Masamura S., Santner SJ., Heitjan DF., Santen RJ. Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J Clin Endocrinol Metab 1995;80:2918-25.
8. Stephen RL., Shaw LE., Larsen C., Corcoran D., Darbre PD. Insulin-like growth factor receptor levels are regulated by cell density and by long-term estrogen deprivation in MCF7 human breast cancer cells. J Biol Chem 2001;276:40080-6.
9. Chan CM., Martin LA., Johnston SR., Ali S., Dowsett M. Molecular changes associated with the acquisition of oestrogen hyper-sensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation. J Steroid Biochem Mol Biol 2002;81:333-41.
10. Jeng MH., Shupnik MA., Ḇender TP., Westin EH., Bandyopad-hyay D., Kumar R., Masamura S., Santen RJ. Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells. Endocrinology 1998;139:4164-74.
11. Staka CM., Nicholson RI., Gee JM. Acquired resistance to oestrogen deprivation: role for growth factor signaling kinases/oes-trogen receptor cross-talk revealed in new MCF-7X model. Endocr Relat Cancer 2005;12:S85-97.
12. Saceda M., Lippman ME., Chambon P., Lindsey RL., Ponglikit-mongkol M., Puente M., Martin MB. Regulation of the estrogen receptor in MCF-7 cells by estradiol. Mol Endocrinol 1988;2: 1157-62.
13. Shaw LE., Sadler AJ., Pugazhendhi D., Darbre PD. Changes in oestrogen receptor-α and -β during progression to acquired resistance to tamoxifen and fulvestrant (Faslodex, ICI 182,780) in MCF7 human breast cancer cells. J Steroid Biochem Mol Biol 2006;99:19-32.
14. Santen RJ., Song RX., Zhang Z., Kumar R., Jeng MH., Masamura S., Lawrence J Jr., MacMahon LP., Yue W., Berstein L. Adaptive hypersensitivity to estrogen: mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment. J Steroid Biochem Mol Biol 2005;95:155-65.
15. Daly RJ., Darbre PD. Interaction of growth factors during progression towards steroid independence in T-47-D human breast cancer cells. J Cell Biochem 1990;43:199-211.
16. Lippman ME., Dickson RB., editors. Regulatory mechanisms in breast cancer. Boston., MA: Kluwer Academic., 1990.
17. Herman ME., Katzenellenbogen BS. Alterations in transforming growth factor-α and -β production and cell responsiveness during progression of MCF-7 human breast cancer cells to estrogen-autonomous growth. Cancer Res 1994;54:5867-74.
18. Shim WS., Conaway M., Masamura S. Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo. Endocrinology 2000;141:396-405.
19. Santen R., Jeng MH., Wang JP. Adaptive hypersensitivity to estradiol: potential mechanism for secondary hormonal responses in breast cancer patients. J Steroid Biochem Mol Biol 2001;79:115-25.
20. Yue W., Wang JP., Conaway M., Masamura S., Li Y., Santen RJ. Activation of the MAPK pathway enhances sensitivity of MCF-7 breast cancer cells to the mitogenic effect of estradiol. Endocrinology 2002;143:3221-9.
21. Martin LA., Farmer I., Johnston SR., Ali S., Marshall C., Dowsett M. Enhanced estrogen receptor (ER) α, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J Biol Chem 2003;278:30458-68.
22. Yue W., Wang JP., Conaway MR., Li Y., Santen RJ. Adaptive hypersensitivity following long-term estrogen deprivation: involvement of multiple signal pathways. J Steroid Biochem Mol Biol 2003;86:265-74.
23. Sabnis GJ., Jelovac D., Long B., Brodie A. The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation. Cancer Res 2005;65: 3903-10.
24. Yamnik RL., Digilova A., Davis DC., Brodt ZN., Murphy CJ., Holz MK. S6 kinase 1 regulates estrogen receptor a in control of breast cancer cell proliferation. J Biol Chem 2009;284: 6361-9.
25. Yue W., Wang J., Li Y., Fan P., Santen RJ. Farnesylthiosalicylic acid blocks mammalian target of rapamycin signaling in breast cancer cells. Int J Cancer 2005;117:746-54.
26. Santen RJ., Song RX., Masamura S., Yue W., Fan P., Sogon T., Hayashi S., Nakachi K., Eguchi H. Adaptation to estradiol deprivation causes up-regulation of growth factor pathways and hypersensitivity to estradiol in breast cancer cells. Adv Exp Med 2008;630:19-34.
27. Di Cosimo S., Baselga J. Targeted therapies in breast cancer: where are we now? Eur J Cancer 2008;44:2781-90.
28. Weinstein IB., Joe A. Oncogene addiction. Cancer Res 2008; 68:3077-80.
29. Sadler AJ., Pugazhendhi D., Darbre PD. Use of global gene expression patterns in mechanistic studies of oestrogen action in MCF7 human breast cancer cells. J Steroid Biochem Mol Biol 2009;114:21-32.
30. Soule HD., Vazquez J., Long A., Albert S., Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 1973;51:1409-16.
31. Osborne CK., Bolan G., Monaco ME., Lippman ME. Hormone responsive human breast cancer in long-term tissue culture: effect of insulin. Proc Natl Acad Sci USA 1976;73:4536-40.
32. Osborne CK., Hobbs K., Trent JM. Biological differences among MCF-7 human breast cancer cell lines from different laboratories. Breast Cancer Res Treat 1987;9:111-21.
33. Darbre PD., Daly RJ. Effects of oestrogen on human breast cancer cells in culture. Proc R Soc Edinb 1989;95B:119-32.
34. Keydar I., Chen L., Karby S., Weiss FR., Delarea J., Radu M., Chaitcik S., Brenner HJ. Establishment and characterization of a cell line of human breast carcinoma origin. Eur J Cancer 1979;15:659-70.
35. Engel LW., Young NA., Tralka TS., Lippman ME., O'Brien SJ., Joyce MJ. Establishment and characterization of three new continuous cell lines derived from human breast carcinomas. Cancer Res 1978;38:3352-64.
36. Darbre P., Yates J., Curtis SA., King RJ. Effect of estradiol on human breast cancer cells in culture. Cancer Res 1983;43: 349-54.
37. Karey KP., Sirbasku DA. Differential responsiveness of human breast cancer cell lines MCF-7 and T47D to growth factors and 17β-estradiol. Cancer Res 1988;48:4083-92.
38. Stewart AJ., Johnson MD., May FE., Westley BR. Role of insulin-like growth factors and the type 1 insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. J Biol Chem 1990;265:21172-8.
39. Dhillon AS., Hagan S., Rath O., Kolch W. MAPkinase signaling pathways in cancer. Oncogene 2007;26:3279-90.
40. Alessi DR., Cuenda A., Cohen P., Dudley DT., Saltiel AR. PD098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 1995;270:27489-94.
41. Favata MF., Horiuchi KY., Manos EJ., Daulerio AJ., Stradley DA., Feeser WS., VanDyk DE., Pitts WJ., Earl RA., Hobbs F., Copeland RA., Magolda R., Scherle PA., Trzaskos JM. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 1998;273:18623-32.
42. Yuan TL., Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008;27:5497-510.
43. Vlahos CJ., Matter WF., Hui KY., Brown RF. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 1994;269: 5241-8.
44. Adi S., Wu NY., Rosenthal SM. Growth factor-stimulated phos-phorylation of Akt and p70S6K is differentially inhibited by LY294002 and Wortmannin. Endocrinology 2001;142:498-501.
45. Riedemann J., Sohail M., Macaulay VM. Dual silencing of the EGF and type 1 IGF receptors suggests dominance of IGF signaling in human breast cancer cells. Biochem Biophys Res Commun 2007;355:700-6.
46. Girnita A., Girnita L., del Prete F., Bartolazzi A., Larsson O., Axel-son M. Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res 2004; 64:236-42.
47. Sarbassov DD., Ali SM., Sabatini DM. Growing roles for the mTOR pathway. Curr Opin Cell Biol 2005;17:596-603.
48. Ray S., Fry MJ., Darbre PD. Enhanced sensitivity to rapamycin following long-term oestrogen deprivation in MCF-7, T-47-D and ZR-75-1 human breast cancer cells. J Endocrinol 2011; 208:21-9.
49. Milazzo G., Giorgino F., Damante G., Sung C., Stampfer MR., Vigneri R., Goldfine ID., Belfiore A. Insulin receptor expression and function in human breast cancer cell lines. Cancer Res 1992;52:3924-30.
50. Dufourney B., Albas J., van Teeffelen AA. Mitogenic signaling of insulin-like growth factor 1 in MCF-7 human breast cancer cells requires phosphatidylinositol 3-kinase and is independent of mitogen-activated protein kinase. J Biol Chem 1997;272: 31163-71.
51. Gualberto A., Pollak M. Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene 2009;28:3009-21.
52. Carracedo A., Ma L., Teruya-Feldstein J., Rojo F., Salmena L., Alimonti A., Egia A., Sasaki AT., Thomas G., Kozma SC., Papa A., Nardella C., Cantley LC., Baselga J., Pandolfi PP. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008;118:3065-74.
53. Baselga J., Semiglazov V., van Dam P., Manikhas A., Bellet M., Mayordomo J., Campone M., Kubista E., Greil R., Bianchi G., Steinseifer J., Molloy B., Tokaji E., Gardner H., Phillips P., Stumm M., Lane HA., Dixon JM., Jonat W., Rugo HS. Phase II randomised study of neoadjuvant Everolimus plus Letrozole compared with placebo plus Letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009;27:2630-7.
54. Ellard SL., Clemons M., Glemon KA., Norris B., Kennecke H., Chia S., Pritchard K., Eisen A., Vandenberg T., Taylor M., Sauer-brei E., Mischaeli M., Huntsman D., Walsh W., Olivo M., McIn-tosh L., Seymour L. Randomized phase II study comparing two schedules of Everolimus in patients with recurrent/metastatic breast cancer: NCIC clinical trials group IND.163. J Clin Oncol 2009;27:4536-41.
55. Dowling RJ., Zakikhani M., Fantus IG., Pollak M., Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 2007; 67:10804-12.
56. Bodmer M., Meier C., Krahenbuhl S., Jick SS., Meier CR. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 2010;33:1304-8.
57. Gonzalez-Angulo AM., Meric-Bernstam F. Metformin: a therapeutic opportunity in breast cancer. Clin Cancer Res 2010;16: 1695-700.
58. O'Reilly KE., Rojo F., She QB., Solit D., Mills GB., Smith D., Lane H., Hofmann F., Hicklin DJ., Ludwig DL., Baselga J., Rosen N. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006;66:1500-8.